Treatment Options in Degenerative Cerebellar Ataxia: A Systematic Review

Abstract

<p id="d5032235e167">The etiology of cerebellar ataxia ( <span style="fixed-case">CA</span>) is heterogeneous and includes easily identified and often reversible causes (i.e., drug toxicity and vitamin B12 deficiency) as well as irreversible degenerative conditions. It is the latter that poses a significant therapeutic challenge for practitioners treating this population of patients. To date, there are no U.S. <span style="fixed-case">Food and Drug Administration–</span>approved medications for the treatment of <span style="fixed-case">CA</span>. The literature, consisting mostly of case reports, case series, and small clinical trials, is sparse and scattered. These studies are difficult to translate clinically because they often describe diverse study populations with various identified and unidentified genetic etiologies. In addition, the reported treatment duration is often brief, and it is uncertain whether any of these options provide substantially lasting benefits. In this article, we review published reports and studies to aid the practitioner counseling patients with degenerative ataxias. </p>